Preparing for the worst

| | Cardiovascular Business | Structural Heart Disease

As we approach the summer season of doomsday movies in all their cinematic gore-y, it may be no surprise that nuclear catastrophe enters into a few imaginations. But at the FDA, it is science and not science fiction that is under discussion as the agency reviews an animal study on Amgen’s leukocyte growth factors as a nuclear countermeasure. The FDA will discuss whether a human study is warranted on May 3. The Bloomberg article includes a link to the FDA backgrounder.

Amgen drugs may boost survival during a nuclear attack

Related Content

American Heart Association announces late-breaking research for Scientific Sessions 2024
Progress in tricuspid valve care and TAVR on full display at TCT 2024
Boston Scientific TAVR valve comes up short in comparison with Medtronic, Edwards devices
TTVR with Evoque device linked to substantial benefits after 1 year
TAVR linked to better outcomes than surgery for women, pooled analysis confirms
Treating asymptomatic aortic stenosis with TAVR linked to significant benefits

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup